Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_assertion type Assertion NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_head.
- NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_assertion description "[These studies highlight the risks of targeting PI4KA as an anti-hepatitis C virus strategy and also point to important distinctions between genetic and pharmacological studies when selecting host factors as putative therapeutic targets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_provenance.
- NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_assertion evidence source_evidence_literature NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_provenance.
- NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_assertion SIO_000772 24415756 NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_provenance.
- NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_assertion wasDerivedFrom befree-20150227 NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_provenance.
- NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_assertion wasGeneratedBy ECO_0000203 NP625875.RAphgDARxZyJ0diWIGTYnYqqCxdVFCg52uJ6dPr-y00Gs130_provenance.